Boiko A N, Batysheva T T, Minaeva N G, Babina L A, Vdovichenko T V, Zhuravleva E Yu, Shikhkerimov R K, Malykhina E A, Khozova A A, Zaitsev K A, Kostenko E V
Department of Neurology and Neurosurgery, Russian State Medical University, Moscow, Russia.
Neurosci Behav Physiol. 2008 Nov;38(9):933-6. doi: 10.1007/s11055-008-9085-3.
Despite the significant symptomatic effects of levodopa, stable 24-h treatment responses are in the vast majority of patients replaced 2-3 years from the start of treatment by oscillations in motor symptoms (fluctuation, dyskinesia), amelioration of which requires addition of constant (physiological) stimulation of postsynaptic dopamine receptors. To some extent this is provided by Stalevo, which contains levodopa and two enzyme inhibitors: the DDC inhibitor carbidopa and the COMT inhibitor entacapone. The results obtained in the present study demonstrated the advantages of Stalevo over traditional agents in patients with the "wearing off" and "on-off" phenomena.
尽管左旋多巴具有显著的症状改善作用，但在绝大多数患者中，从治疗开始2 - 3年后，稳定的24小时治疗反应会被运动症状的波动（异动症）所取代，而改善这种情况需要增加对突触后多巴胺受体的持续（生理性）刺激。在一定程度上，Stalevo（左旋多巴复合制剂）能提供这种刺激，它含有左旋多巴和两种酶抑制剂：DDC抑制剂卡比多巴和COMT抑制剂恩他卡朋。本研究获得的结果表明，在出现“剂末现象”和“开关现象”的患者中，Stalevo比传统药物更具优势。
